A Medical Device Daily
PLC Systems (Franklin, Massachusetts), a company focused on innovative cardiac and vascular medical device-based technologies, reported that it has entered into a five year exclusive agreement with Discomed Comercio de Produtos Hospitalares (Porto Alegre, Brazil), for distribution of its RenalGuard System in Brazil.
Discomed is an established distributor of medical technology and devices in Brazil. The company will target early adopters who recognize the benefits of utilizing the unique fluid balancing capabilities of RenalGuard in a cath lab setting during cardiovascular imaging procedures for patients at higher risk of contrast-induced nephropathy (International report).
Discomed is applying for the needed registration through ANVISA, the Brazilian registration authority, and expects approval in about 9 months.
PLC's President/CEO, Mark Tauscher, said, "We are very pleased to extend the launch of our RenalGuard technology to another important region, South America, working with our newest partner, Discomed. We see significant market potential for RenalGuard in Brazil due to its large population, and the high number of cardiovascular procedures undertaken each year.
Brazil joins Italy, Spain, Bangladesh and Pakistan as countries where PLC has now launched RenalGuard. PLC received the CE mark for the system in late December 2007, and concluded its pilot safety trial in the U.S. late in 2007.
Health Robotics in Korean distribution contract
Health Robotics (Bolzano, Italy) reported that Innomed/BioRobotics, on the heels of its prior market success with Oncology Surgery robots, has exclusively selected Health Robotics' CytoCare Robot to reach its objective to become the gold standard for Oncology Robotics IV Admixtures in the Republic of Korea and synergistically provide an end-to-end Cancer Robotics solution.
"We are very pleased to reach 100% territorial coverage for CytoCare in Asia-Pacific. This new partnership culminates a great year for Health Robotics' CytoCare adoption and unprecedented market success vs. our competition, on the heels of similar new partnerships signed this summer and fall in Oceania, China, Taiwan, and South East Asia," said Werner Rainer, Health Robotics' CEO.
CytoCare is a robotic system designed for the safe and sterile preparation of patient-specific hazardous IV admixtures for chemotherapy, monoclonal antibody therapy, and gene therapy.
Founded in 1995, Innomed/BioRobotics is currently the leading medical robotics supplier and the second largest medical importing business in the Republic of Korea with $27 million import volume during the year 2008. The company originally started in the aesthetic laser surgery and cryosurgery medical sectors and further expanded into robotic surgery in 2005.
ABL's TherapyEdge products now in Brazil
Advanced Biological Laboratories (ABL; Luxembourg) reported that Centro de Genomas (Sao Paulo, Brazil) will provide to the private and public sectors throughout Brazil, the ABL TherapyEdge products in Portuguese language. Beginning immediately Centro de Genomas will be supporting TherapyEdge, ViroScore Suite and other online services primarily in the field of HIV/AIDS and viral hepatitis.
Centro de Genomas will offer customers expanded training and support via workshops and in-office training.
ABL and Centro de Genomas will work closely to develop strategic partnerships in Brazil. The combined alliance will seek to find a national or a regional corporate Diagnostic distributor for ABL's products line.
In accordance with its full commitment to support research, which include free medical tools and exchange of knowledge for the benefit of humanity, ABL has proposed Centro de Genomas to be in contact with any researcher, university and non-profit institution in Brazil to offer them royalty free sublicense rights on ABL U.S. patents
"We're extremely pleased about this new partnership. We believe Brazilian infectious diseases specialists and patients will see the benefits of an integrated IT solution such as TherapyEdge. We have now TherapyEdge customized for the Brazilian market which should ease its widespread use," said Chalom Sayada, CEO of ABL.